Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
20/20 BioLabs entered a standstill agreement with Streeterville Capital on July 16, 2026, restricting conversions of Series E Preferred Stock to common stock for 120 days.
GAAP income before taxes was $16.3 million, or $0.12 of diluted earnings per share (EPS), and distributable earnings was $30.8 million, or $0.24 of distributable EPS for Q2 2026.
High-resolution airborne geophysics defined over 9 km of rare earth exploration corridors in the Velhinhas project, extending mineralization south of Monte Alto.
American Fusion filed 19 new U.S. patent applications, bringing its total to 76 as part of a strategy to protect innovations across the Texatron™ platform.
